The introduction of biosimilar products or products approved based on demonstrating that it is highly similar to an FDA-approved biologic product, has opened many possibilities in the field of pharmaceuticals. In this session, this panel of thought leaders will explore the impact of biosimilars on patient care, how to get buy-in on biosimilars for clinicians, and opportunities for use of biosimilars in supply chain shortages.
1. Define biosimilars and their uses.
2. Outline how to get buy-in on biosimilars from clinicians.
3. Analyze the impact of biosimilars on patient care.
4. Demonstrate opportunities for biosimilars with supply chain shortages.